FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3014544167> ?p ?o ?g. }

• W3014544167 endingPage "721" @default.
• W3014544167 startingPage "712" @default.
• W3014544167 abstract "Abstract Background Recent clinical trials have evaluated angiotensin-converting enzyme (ACE) inhibitors (ACEis), angiotensin receptor blockers (ARBs), and beta blockers (BBs) in relation to cardiotoxicity in patients with cancer, typically defined by ejection fraction declines. However, these trials have not examined long-term, hard clinical endpoints. Within a prospective study, we examined the risk of heart failure (HF) and coronary heart disease (CHD) events in relation to use of commonly used antihypertensive medications, including ACEis/ARBs, BBs, calcium channel blockers (CCB), and diuretics, comparing women with and without cancer. Materials and Methods In a cohort of 56,997 Women's Health Initiative study participants free of cardiovascular disease who received antihypertensive treatment, we used multivariable-adjusted Cox regression models to calculate the hazard ratios (HRs) of developing CHD, HF, and a composite outcome of cardiac events (combining CHD and HF) in relation to use of ACEis/ARBs, CCBs, or diuretics versus BBs, separately in women with and without cancer. Results Whereas there was no difference in risk of cardiac events comparing ACEi/ARB with BB use among cancer-free women (HR = 0.99 [0.88–1.12]), among cancer survivors ACEi/ARB users were at a 2.24-fold risk of total cardiac events (1.18–4.24); p-interaction = .06). When investigated in relation to CHD only, an increased risk was similarly observed in ACEi/ARB versus BB use for cancer survivors (HR = 1.87 [0.88–3.95]) but not in cancer-free women (HR = 0.91 [0.79–1.06]; p-interaction = .04). A similar pattern was also seen in relation to HF but did not reach statistical significance (p-interaction = .23). Conclusion These results from this observational study suggest differing risks of cardiac events in relation to antihypertensive medications depending on history of cancer. Although these results require replication before becoming actionable in a clinical setting, they suggest the need for more rigorous examination of the effect of antihypertensive choice on long-term cardiac outcomes in cancer survivors. Implications for Practice Although additional research is needed to replicate these findings, these data from a large, nationally representative sample of postmenopausal women indicate that beta blockers are favorable to angiotensin-converting enzyme inhibitors in reducing the risk of cardiac events among cancer survivors. This differs from the patterns observed in a noncancer cohort, which largely mirrors what is found in the randomized clinical trials in the general population." @default.
• W3014544167 created "2020-04-10" @default.
• W3014544167 creator A5000172773 @default.
• W3014544167 creator A5001693847 @default.
• W3014544167 creator A5004840750 @default.
• W3014544167 creator A5005256434 @default.
• W3014544167 creator A5006914481 @default.
• W3014544167 creator A5007771464 @default.
• W3014544167 creator A5009980709 @default.
• W3014544167 creator A5018618797 @default.
• W3014544167 creator A5020437483 @default.
• W3014544167 creator A5027294794 @default.
• W3014544167 creator A5027561648 @default.
• W3014544167 creator A5030728905 @default.
• W3014544167 creator A5031050771 @default.
• W3014544167 creator A5034251151 @default.
• W3014544167 creator A5051566073 @default.
• W3014544167 creator A5062804698 @default.
• W3014544167 creator A5072032232 @default.
• W3014544167 creator A5074440435 @default.
• W3014544167 creator A5086484380 @default.
• W3014544167 creator A5086837796 @default.
• W3014544167 date "2020-04-06" @default.
• W3014544167 modified "2023-09-30" @default.
• W3014544167 title "Cardiovascular Outcomes in Relation to Antihypertensive Medication Use in Women with and Without Cancer: Results from the Women's Health Initiative" @default.
• W3014544167 cites W1489904087 @default.
• W3014544167 cites W1492360552 @default.
• W3014544167 cites W1965189531 @default.
• W3014544167 cites W1988847150 @default.
• W3014544167 cites W2017626575 @default.
• W3014544167 cites W2018719108 @default.
• W3014544167 cites W2036172035 @default.
• W3014544167 cites W2038953523 @default.
• W3014544167 cites W2045806344 @default.
• W3014544167 cites W2047516551 @default.
• W3014544167 cites W2057847137 @default.
• W3014544167 cites W2076326930 @default.
• W3014544167 cites W2077210366 @default.
• W3014544167 cites W2088229392 @default.
• W3014544167 cites W2096597021 @default.
• W3014544167 cites W2099358413 @default.
• W3014544167 cites W2100376862 @default.
• W3014544167 cites W2102708069 @default.
• W3014544167 cites W2103320867 @default.
• W3014544167 cites W2104841007 @default.
• W3014544167 cites W2114333967 @default.
• W3014544167 cites W2120914209 @default.
• W3014544167 cites W2126125759 @default.
• W3014544167 cites W2129316643 @default.
• W3014544167 cites W2129736317 @default.
• W3014544167 cites W2129783757 @default.
• W3014544167 cites W2151145647 @default.
• W3014544167 cites W2153523117 @default.
• W3014544167 cites W2156698079 @default.
• W3014544167 cites W2170479821 @default.
• W3014544167 cites W2170912509 @default.
• W3014544167 cites W2182067229 @default.
• W3014544167 cites W2279656465 @default.
• W3014544167 cites W2290627980 @default.
• W3014544167 cites W2297753288 @default.
• W3014544167 cites W2298838354 @default.
• W3014544167 cites W2345847191 @default.
• W3014544167 cites W2413293160 @default.
• W3014544167 cites W2558002415 @default.
• W3014544167 cites W2591402457 @default.
• W3014544167 cites W2789300675 @default.
• W3014544167 cites W2944153890 @default.
• W3014544167 cites W4242459468 @default.
• W3014544167 cites W4243147470 @default.
• W3014544167 doi "https://doi.org/10.1634/theoncologist.2019-0977" @default.
• W3014544167 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7418354" @default.
• W3014544167 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32250503" @default.
• W3014544167 hasPublicationYear "2020" @default.
• W3014544167 type Work @default.
• W3014544167 sameAs 3014544167 @default.
• W3014544167 citedByCount "2" @default.
• W3014544167 countsByYear W30145441672023 @default.
• W3014544167 crossrefType "journal-article" @default.
• W3014544167 hasAuthorship W3014544167A5000172773 @default.
• W3014544167 hasAuthorship W3014544167A5001693847 @default.
• W3014544167 hasAuthorship W3014544167A5004840750 @default.
• W3014544167 hasAuthorship W3014544167A5005256434 @default.
• W3014544167 hasAuthorship W3014544167A5006914481 @default.
• W3014544167 hasAuthorship W3014544167A5007771464 @default.
• W3014544167 hasAuthorship W3014544167A5009980709 @default.
• W3014544167 hasAuthorship W3014544167A5018618797 @default.
• W3014544167 hasAuthorship W3014544167A5020437483 @default.
• W3014544167 hasAuthorship W3014544167A5027294794 @default.
• W3014544167 hasAuthorship W3014544167A5027561648 @default.
• W3014544167 hasAuthorship W3014544167A5030728905 @default.
• W3014544167 hasAuthorship W3014544167A5031050771 @default.
• W3014544167 hasAuthorship W3014544167A5034251151 @default.
• W3014544167 hasAuthorship W3014544167A5051566073 @default.
• W3014544167 hasAuthorship W3014544167A5062804698 @default.
• W3014544167 hasAuthorship W3014544167A5072032232 @default.
• W3014544167 hasAuthorship W3014544167A5074440435 @default.
• W3014544167 hasAuthorship W3014544167A5086484380 @default.
• W3014544167 hasAuthorship W3014544167A5086837796 @default.

• next